Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer

NCT06855524

Status	RECRUITING
Phase	Phase 2
Sponsor	Mayo Clinic
Enrollment	34 participants

Key Eligibility Criteria

Inclusion (12)

- Age e 18 years
- Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1
- Starting platinum-based doublet/triplet therapy for gynecologic or gastrointestinal cancer in the non-curative setting, with at least 16 weeks of chemotherapy and/or immunotherapy planned prior to registration; able to start study treatment d 7 days prior to starting chemotherapy
- Life expectancy at least 6 months
- Hemoglobin e 10 g/dL (obtained d 30 days prior to registration)

... and 7 more (see full listing online)

Exclusion (12)

- Known hypersensitivity to fucoidan or seaweed products
- Currently using any other pharmacologic agents to specifically treat fatigue including psychostimulants or antidepressants. Note: Antidepressants used to treat items other than fatigue (such as hot flashes or depression) are allowed if the patient has been on a stable dose for e 1 month prior to registration and plans to continue such for 8 weeks. Exercise is allowed
- Psychiatric disorder such as untreated/uncontrolled depression, manic depressive disorder, obsessive compulsive disorder or schizophrenia (defined per medical history)
- Surgery that required general anesthetic d 4 weeks prior to registration
- Malnutrition, active infection, severe depression, significant pulmonary disease, and/or cardiovascular disease that the attending physician feels could be causing the patient's fatigue

... and 7 more (see full listing online)

Locations (1 total)

Mayo Clinic in Arizona, Scottsdale, Arizona, United States